Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. (9th September 2022)

• Record Type: Journal Article
• Authors: Muniesa, Cristina; Gallardo, Fernando; García‐Doval, Ignacio; Estrach, M. Teresa; Combalia, Andrea; Morillo‐Andújar, Mercedes; De la Cruz‐Vicente, Fátima; Machan, Salma; Moya‐Martínez, Cristina; Rovira, Roger; Sanchez‐Gonzalez, Blanca; Acebo, Elvira; Amutio, Elena; Peñate, Yeray; Losada‐Castillo, Maria del Carmen; García‐Muret, M. Pilar; Iznardo, Helena; Román‐Curto, Concepción; Cañueto, Javier; Fernández‐de‐Misa, Ricardo; Flórez, Ángeles; Izu, Rosa María; Torres‐Navarro, Ignacio; Zayas, Ana; Pérez‐Paredes, Gema; Blanes, Mar; Yanguas, J. Ignacio; Pérez‐Ferriols, Amparo; Callejas‐Charavia, Marta; Ortiz‐Romero, Pablo Luis; Pérez‐Gil, Amalia; Prieto‐Torres, Lucia; González‐Barca, Eva; Servitje, Octavio;
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 37:Number 1(2023)
• Page Start: 57
• Page End: 64
• Publication Date: 2022-09-09
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.18563
• Languages: English
• ISSNs: 0926-9959

Abstract

ABSTRCT: Background: Brentuximab vedotin (BV) has been approved for CD30‐expressing cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results: Sixty‐seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty‐eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow‐up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow‐up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions: These results confirm the efficacy and safety of BV in patients with advanced‐stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.